Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2) (2.04.02)
Summary
Blue Shield of California's policy 2.04.02 states that genetic testing for BRCA1, BRCA2 and PALB2 variants may be considered medically necessary in cancer-affected individuals who meet the listed personal or family history criteria, such as breast cancer diagnosed at age 45 years or younger, personal history of epithelial ovarian carcinoma, or personal history of exocrine pancreatic cancer. BRCA1 and BRCA2 testing outside those criteria, PALB2 testing for individuals who do not meet the criteria, and testing in minors are considered investigational. This version is effective November 1, 2026, and the policy statement has no changes from the previous version.
Get alerts when payers change rules like this one
We check Blue Shield of California and other payers every day and email you when a change matches your specialty and state.